Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PIPE-307 by Janssen Pharmaceutica for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
PIPE-307 is under clinical development by Janssen Pharmaceutica and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According...